Neuropharmacology in Traumatic Brain Injury.

Autor:	Sanchez G; Physical Medicine & Rehabilitation Residency Program, Greater Los Angeles VA Healthcare System, 11301 Wilshire Boulevard, Los Angeles, CA 90073, USA., Byl M; Physical Medicine & Rehabilitation Residency Program, Greater Los Angeles VA Healthcare System, 11301 Wilshire Boulevard, Los Angeles, CA 90073, USA., Pham QG; Division of Physical Medicine and Rehabilitation, Department of Medicine, David Geffen School of Medicine at UCLA; Physical Medicine & Rehabilitation Residency Program, Greater Los Angeles VA Healthcare System, David Geffen School of Medicine at UCLA., Eapen BC; Division of Physical Medicine and Rehabilitation, University of California, Los Angeles (UCLA); Physical Medicine and Rehabilitation Service, VA Greater Los Angeles Healthcare System; David Geffen School of Medicine at UCLA. Electronic address: Blessen.Eapen2@va.gov.
Jazyk:	angličtina
Zdroj:	Physical medicine and rehabilitation clinics of North America [Phys Med Rehabil Clin N Am] 2024 Aug; Vol. 35 (3), pp. 619-636. Date of Electronic Publication: 2024 Apr 06.
DOI:	10.1016/j.pmr.2024.02.001
Abstrakt:	One of the primary goals in traumatic brain injury (TBI) treatment is to minimize secondary brain damage and promote neuroprotection. In TBI rehabilitation, we seek to facilitate neurologic recovery and restore what independence is possible given a patient's physical and cognitive impairments. These goals must be balanced with treatment of the various symptoms that may occur following TBI. This is challenging given the fact that many of the typical treatments for certain symptoms also come with side effects which could be problematic in the TBI population. Competing Interests: Disclosure None. (Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu